Ibio 8-K Filings

iBio, Inc. appointed endocrinologist Molly Carr, M.D., as Chief Medical Officer effective July 31, 2026, to lead global clinical strategy, medical affairs and regulatory initiatives for its obesity and cardiometabolic pipeline. She brings more than 30 years of clinical, academic and biopharmaceutical experience, including senior roles at Eli Lilly and GlaxoSmithKline.

Under an employment agreement, Dr. Carr will receive an annual base salary of $470,000 and an annual target cash bonus equal to 40% of salary. As a material inducement to join, she was granted a non-qualified stock option to purchase 430,000 shares at $1.40 per share, with 25% vesting after one year and the remainder in 36 monthly installments. If terminated without Cause or resigning for Good Reason, she may receive salary continuation, pro rata or target bonus, COBRA coverage, and, following a Sale Event, accelerated vesting of time-based equity awards, subject to conditions.

iBio, Inc. plans to hold its 2026 Annual Meeting of Stockholders on October 14, 2026, with stockholders of record at the close of business on September 1, 2026 entitled to vote. The specific time and location will be provided in the definitive proxy statement.

Because this meeting date is more than 30 days earlier than the 2025 annual meeting, previously disclosed proposal deadlines no longer apply. Stockholder proposals for inclusion in the proxy materials under Rule 14a-8 must be received by August 1, 2026. Proposals or director nominations not under Rule 14a-8, submitted under the company’s bylaws, must be received by July 27, 2026. To comply with universal proxy rules, stockholders soliciting proxies for alternative director nominees must provide the notice required by Rule 14a-19 by August 15, 2026, 60 days before the meeting date.

iBio, Inc. reported new preclinical results from an obese non-human primate study of IBIO-610, a potentially first-in-class Activin E antibody for obesity and related diseases. After a single dose, active Activin E in blood fell in all treated animals and stayed suppressed for eight weeks.

Active Activin E levels were reduced by 98% at week 4 and 97% at week 8 compared with baseline, with levels below the limits of the assay at both time points. The company states this supports the potential for strong pathway inhibition and an infrequently dosed, long-acting antibody.

The data also suggest IBIO-610 may promote fat-selective weight loss while preserving lean mass. In obese primates, adding IBIO-610 to semaglutide produced greater visceral and total fat loss and cut lean mass loss by 73% versus semaglutide alone, supporting its potential as both a stand-alone and GLP-1-complementary therapy. The full dataset will be presented at the 2026 EASD Annual Meeting in Milan.

iBio, Inc. reported third-quarter fiscal 2026 results, highlighting pipeline progress alongside wider losses. The company recorded no revenue for the quarter ended March 31, 2026, while research and development expenses rose to $3.3 million from $1.9 million and general and administrative expenses increased to $5.1 million from $3.0 million, driven mainly by a $2.5 million impairment of the IBIO-101 intangible asset.

Operating loss was $8.4 million and net loss was $7.7 million, or $0.06 per share, compared with a $4.9 million net loss, or $0.49 per share, a year earlier. iBio held $74.8 million in cash, cash equivalents and investments in debt securities as of March 31, 2026, and received approximately $17 million in gross proceeds from warrant exercises in the fourth fiscal quarter, which the company states extend its cash runway into the fourth quarter of fiscal 2028.

Strategically, iBio obtained regulatory clearance in Australia to initiate a phase 1 clinical trial of obesity candidate IBIO-600, reported new obese non-human primate data for IBIO-610 showing a 6.7% reduction in visceral fat and 5.2% reduction in total fat mass, and expanded its pipeline with a bispecific antibody targeting pulmonary hypertension associated with heart failure with preserved ejection fraction.

iBio, Inc. reported changes to its Board of Directors. The Board appointed Dr. Elizabeth Stoner as a Class II director and member of the Compensation Committee, effective May 7, 2026, with a term running until the 2028 annual meeting of stockholders.

Dr. Stoner brings more than 35 years of biotech R&D leadership, including senior roles at Merck Research Laboratories, Semma Therapeutics, and Rhythm Pharmaceuticals, and currently serves as an Entrepreneur Partner at MPM BioImpact. She joins as an independent director, while Evert (Eef) Schimmelpennink resigned from the Board and the Compensation Committee, with the company stating his resignation was not due to any disagreement over operations, policies, or practices.

For the fiscal year ending June 30, 2026, Dr. Stoner will receive the Company’s standard non-employee director compensation, including a $40,000 annual Board fee, a $7,500 annual Compensation Committee fee, and eligibility for an initial stock option grant vesting over 36 months, along with future equity awards under standard policies.

iBio, Inc. filed an amended report to correct and update details about its Series G warrants and related share counts, and to describe progress on its IBIO-600 program. The amendment clarifies that Series G warrants to purchase up to 35,770,000 shares of common stock now expire at 5:00 p.m. New York City time on May 20, 2026, based on a recent clinical milestone announcement.

The company previously issued pre-funded warrants for up to 71,540,000 shares and matching Series G and Series H warrants in an August 2025 financing. As of April 17, 2026, Series G warrants to buy up to 11,065,000 shares remain outstanding, and common shares outstanding total 36,143,561. The filing also notes Australian regulatory and ethics approvals enabling a first-in-human Phase 1 clinical trial of IBIO-600, with first participants expected to be dosed in the second quarter of 2026.

iBio, Inc. announced it has received Clinical Trial Notification acknowledgement from Australia’s Therapeutic Goods Administration and ethics approval from a Human Research Ethics Committee, enabling initiation of a first-in-human Phase 1 trial of IBIO-600 in overweight and obese adults in Australia. The company expects to dose the first participant in the second quarter of 2026. IBIO-600 is a long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body composition, potentially complementing GLP-1 therapies. The filing also explains that, following this public announcement, outstanding Series G warrants to purchase up to 27,945,000 shares of common stock will now expire on May 12, 2026, while any Series H warrants issued upon their exercise will expire four years after the 2025 offering closing.

iBio, Inc. filed a Form 8-K describing new preclinical results for IBIO-610, an Activin E antibody candidate being studied for fat-selective weight loss. In obese non-human primates, two once-every-eight-week doses reduced visceral fat by 6.7% and total fat mass by 5.2% despite a high-calorie diet, with only a slight increase in lean mass.

These findings, consistent with prior rodent data and other Activin E–targeting approaches in human trials, support continued evaluation of IBIO-610 for obesity, cardiometabolic and cardiopulmonary diseases. iBio also highlighted strategic expansion into the cardiopulmonary field, including a myostatin x Activin A bispecific antibody program for pulmonary hypertension heart failure with preserved ejection fraction (PH-HFpEF), in an updated corporate presentation.

iBio, Inc. entered into a new at-the-market stock offering program with Jefferies LLC, allowing sales of up to $100,000,000 of common stock under a new Form S-3 shelf registration statement, when declared effective. The company will control sale parameters such as timing, size per trading day, and minimum price, while paying Jefferies a commission of up to 3.0% of gross proceeds plus specified legal and filing-related fees.

iBio also terminated its prior at-the-market program with Chardan Capital Markets and Craig-Hallum Capital Group, which had permitted issuances of up to $7,350,000 of common stock. No further sales will occur under the prior agreement or its related prospectus.

iBio, Inc. reported a larger loss for its fiscal second quarter ended December 31, 2025 while strengthening its balance sheet and advancing its obesity-focused antibody pipeline. The company completed a $26 million private placement led by a biotech investor, receiving net proceeds of approximately $24.4 million in January 2026 and extending its cash runway into the third quarter of fiscal year 2028.

For the quarter, iBio recognized no revenue, compared with $0.2 million a year earlier. Research and development expenses rose to $4.3 million from $1.9 million, driven by higher spending on consultants, outside services, and personnel to progress IBIO-600, IBIO-610 and other preclinical assets. General and administrative expenses increased to approximately $5.2 million from $2.7 million, primarily due to an impairment of the IBIO-101 intangible asset, resulting in a net loss of $8,993 thousand versus $4,364 thousand.

iBio held $52.7 million in cash, cash equivalents and investments in debt securities as of December 31, 2025. Management highlighted initiation of CMC development and toxicology studies for IBIO-610 and IBIO-600 as key steps toward planned human clinical trials.

iBio, Inc. entered into a securities purchase agreement with institutional investors for a private placement priced at-the-market, raising approximately $26 million in gross proceeds. The company agreed to sell 1,408,481 shares of common stock at $2.35 per share and issue pre-funded warrants to purchase up to 9,653,257 additional shares at an exercise price of $0.001 per share, with a purchase price of $2.349 per pre-funded warrant.

The closing is expected on or about January 13, 2026, and iBio plans to use the net proceeds to advance its preclinical cardiometabolic pipeline, including IBIO-610, IBIO-600 and myostatin/activin A bispecific programs, as well as other preclinical assets, and for working capital and general corporate purposes. The company granted investors registration rights for resale of the shares and warrant shares and agreed to temporary restrictions on additional equity issuances and certain corporate actions until the resale registration statement becomes effective or 60 days after closing.

iBio, Inc. reported the results of its Annual Meeting of Stockholders held on November 20, 2025. Stockholders representing 10,566,364 shares were present in person or by proxy, constituting a quorum. Two Class II directors, Dr. Martin Brenner and Dr. Alexandra Kropotova, were elected to three-year terms expiring at the 2028 Annual Meeting.

Stockholders ratified the appointment of Grassi & Co., CPAs, P.C. as independent registered public accounting firm for the fiscal year ending June 30, 2026, with 9,912,837 votes for and 594,576 against. They also approved, on an advisory basis, the executive compensation program, with 4,392,583 votes for and 403,278 against.

In addition, stockholders approved holding future advisory votes on executive compensation every year, with 4,290,210 votes favoring a one-year frequency. Consistent with this vote and the Board’s recommendation, the Company will conduct an annual advisory say-on-pay vote until the next required vote on frequency.

iBio, Inc. filed a Form 8-K to announce that it has updated its corporate presentation. The new investor presentation is furnished as Exhibit 99.1 and is intended for use in meetings with investors, analysts and other stakeholders. The presentation includes forward-looking statements covered by “safe harbor” language under the Private Securities Litigation Reform Act of 1995. iBio notes it has no obligation to update the information in the presentation, although it may choose to do so through future public disclosures.

iBio, Inc. filed a Form 8-K and furnished a press release announcing financial results for the quarter ended September 30, 2025. The disclosure appears under Item 2.02 (Results of Operations and Financial Condition) and the press release is included as Exhibit 99.1.

The company states this information is furnished, not filed, and it is not incorporated by reference into other SEC filings. The report is dated November 12, 2025.

iBio, Inc. reported it has regained compliance with Nasdaq Listing Rule 5550(a)(2) after receiving notice from Nasdaq on November 4, 2025. The rule requires a minimum closing bid price of $1.00 per share. The company had previously been notified on July 29, 2025 that it was out of compliance after its stock closed below $1.00 for 30 consecutive business days from June 13, 2025 to July 28, 2025. Nasdaq has indicated the matter is closed, supporting the company’s continued listing on The Nasdaq Capital Market.

iBio, Inc. announced new preclinical pharmacokinetic data for IBIO-610, a potentially first-in-class Activin E antibody. In obese non-human primates, IBIO-610 showed an extended half-life of 33.2 days. Using an allometric scaling model for half-life–extended antibodies, the company reports a predicted human half-life of up to 100 days, which could lower dosing to once every six months and improve patient experience.

The data will be presented by Cory Schwartz, Ph.D., during an oral session at ObesityWeek 2025 in Atlanta, held November 4–7, 2025. The announcement was shared via press release furnished with this report, which includes forward-looking statement disclosures.

iBio, Inc. filed a Form 8-K to report that it issued a press release announcing its financial results for the fiscal year ended June 30, 2025. The press release is furnished as Exhibit 99.1 to the report.

The company states that the information in Item 2.02 and Exhibit 99.1 is being furnished, not filed, so it is not subject to certain liability provisions and will not be incorporated by reference into other SEC filings. The report is signed on behalf of iBio by Chief Legal Counsel Marc A. Banjak.

iBio, Inc. reported a material event filing that discloses a financing-related package of documents. The filing attaches an underwriting agreement with Leerink Partners as representative of the underwriters, forms for a pre-funded warrant and two series of warrants, a legal opinion and consent from Blank Rome LLP, and two press releases described as a launch release and a pricing release. The filing also includes the interactive cover page data file. The disclosure signals a planned securities offering structure but does not include offering size, pricing terms, or proceeds in the attached exhibit list.

iBio, Inc. filed a current report describing preliminary financial data and an updated business focus on AI-driven obesity and cardiometabolic therapies. On an unaudited basis, the company expects to report cash, cash equivalents and restricted cash of $8.8 million as of June 30, 2025, noting that this figure may change once year-end closing and the audit are completed.

The company outlines a preclinical pipeline centered on antibody therapeutics IBIO-610 and IBIO-600, which target pathways involved in fat-selective weight loss and muscle preservation, including in combination with GLP-1 receptor agonists. iBio also highlights its AI Drug Discovery Platform and related tools, as well as new and expanded risk factors around licensed intellectual property, reliance on AI/ML and third-party data, competitive pressures, regulatory uncertainty for AI, and the inherent difficulty and long timelines of bringing its early-stage product candidates through clinical development.

On June 24, 2025, iBio, Inc. (Nasdaq: IBIO) filed a Form 8-K to inform the market that it has released an updated corporate presentation, dated June 2025. The slide deck, furnished as Exhibit 99.1, will be used in discussions with investors, analysts and other stakeholders. The filing is made under Item 7.01 (Regulation FD Disclosure) and Item 8.01 (Other Events). iBio states that the presentation includes forward-looking statements covered by the Private Securities Litigation Reform Act of 1995 and that the company assumes no obligation to update the material. No financial results, strategic transactions or other material developments are disclosed in this report.